Chen Ling-Zi, Jing Xu-Bin, Chen Xiang, Xie Yan-Chun, Chen Yun, Cai Xian-Bin
Department of Gastroenterology, The First Affiliated Hospital of Shantou University Medical College, 515041 Shantou, Guangdong, China.
Department of Endoscopy Center, Cancer Hospital of Shantou University Medical College, 515041 Shantou, Guangdong, China.
Rev Cardiovasc Med. 2024 Sep 24;25(9):344. doi: 10.31083/j.rcm2509344. eCollection 2024 Sep.
Non-alcoholic fatty liver disease (NAFLD), one of the most common chronic liver diseases with a prevalence of 23%-25% globally, is an independent risk factor for cardiovascular diseases (CVDs). Growing evidence indicates that the development of NAFLD, ranging from non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), advanced fibrosis to cirrhosis, and even hepatocellular carcinoma, is at substantial risk for CVDs, which clinically contribute to increased cardiovascular morbidity and mortality. Non-invasive serum markers assessing liver fibrosis, such as fibrosis-4 (FIB-4) score, aspartate transaminase-to-platelet ratio index (APRI), and NAFLD fibrosis score (NFS), are expected to be useful tools for clinical management of patients with CVDs. This review aims to provide an overview of the evidence for the relationship between the progression of NAFLD and CVDs and the clinical application of non-invasive markers of liver fibrosis in managing patients with CVDs.
非酒精性脂肪性肝病（NAFLD）是全球最常见的慢性肝病之一，患病率为23%-25%，是心血管疾病（CVD）的独立危险因素。越来越多的证据表明，NAFLD的发展，从非酒精性脂肪肝（NAFL）、非酒精性脂肪性肝炎（NASH）、进展性肝纤维化到肝硬化，甚至肝细胞癌，都存在患CVD的重大风险，这在临床上导致心血管发病率和死亡率增加。评估肝纤维化的非侵入性血清标志物，如纤维化-4（FIB-4）评分、天冬氨酸转氨酶与血小板比值指数（APRI）和NAFLD纤维化评分（NFS），有望成为CVD患者临床管理的有用工具。本综述旨在概述NAFLD进展与CVD之间关系的证据，以及肝纤维化非侵入性标志物在CVD患者管理中的临床应用。
